Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2019 02:30 ET | Source: LIDDS AB

Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect

Study confirms Liproca® Depot’s potential as drug treatment for men with prostate cancer who currently are under ‘Active Surveillance’ and receiving no treatment UPPSALA, SWEDEN. LIDDS AB...
August 29, 2019 02:40 ET | Source: LIDDS AB

LIDDS Delårsrapport april - juni 2019

APRIL – JUNI 2019 Nettoomsättningen uppgick till 0,0 (0,0) MSEKKostnaderna uppgick till 3,4 (2,2) MSEKResultatet före och efter skatt uppgick till -3,4 (-2,2) MSEKResultat per aktie uppgick till...
August 28, 2019 04:57 ET | Source: LIDDS AB

LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019

Professor Laurence Klotz, a world leading expert in Active Surveillance of prostate cancer patients, will present the results of the LPC-004 prostate cancer study at the 11th European...
August 19, 2019 10:00 ET | Source: LIDDS AB

LIDDS: Anja Peters becomes new CFO of LIDDS

LIDDS has appointed Anja Peters Ohlsson as new CFO of LIDDS AB and member of the management team. Anja will succeed Bengt Norvik, who will leave his position in September following many years as CFO...
June 18, 2019 02:59 ET | Source: LIDDS AB

LIDDS continues to grow with new hire to manage pre-clinical trials

Erwin Brenndörfer has joined LIDDS as Project Manager Translational Medicine and will be responsible for managing LIDDS growing portfolio of pre-clinical studies as well as continuing the development...
May 16, 2019 12:48 ET | Source: LIDDS AB

Kommuniké från årsstämman i LIDDS

Den 16 maj 2019 hölls årsstämma i LIDDS AB (publ). Nedan följer sammanfattning av de beslut som fattades. Beslut fattades med erforderlig majoritet. Vid stämman var 433 852 (1,88%) av totalt 23...
May 16, 2019 02:50 ET | Source: LIDDS AB

LIDDS Delårsrapport januari - mars 2019

JANUARI - MARS 2019 Nettoomsättningen uppgick till 0,0 (0,0) KSEK Kostnaderna uppgick till 2,5 (2,0) MSEK Resultatet före och efter skatt uppgick till -2,5 (-2,0) MSEK Resultat...
May 15, 2019 02:55 ET | Source: LIDDS AB

LIDDS completes a directed issue raising SEK 8.9 million

The board of directors of LIDDS AB has decided to carry out a directed issue of 641.200 shares at a subscription price of SEK 13.85 per share. LIDDS will through the directed share issue receive...
May 06, 2019 02:45 ET | Source: LIDDS AB

LIDDS: Liproca® Depot open label extension study indicates longer treatment intervals

Preliminary data from a voluntary open label extension (OLE) study indicates that the time to re-treatment with Liproca® Depot in prostate cancer patients is potentially longer than anticipated....
May 02, 2019 02:40 ET | Source: LIDDS AB

LIDDS develops its own proprietary product for intratumoral immunotherapy - Freedom to operate analysis done for the TLR9-agonist project

LIDDS has an ongoing preclinical development program based on a clinical stage TLR9 agonist. The objective is to use a NanoZolid® formulation with the TLR9 agonist as an intratumoral immunotherapy...